Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Simcere Passes EU-GMP Inspection for OTC Diarrhea Treatment

publication date: Aug 23, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharma reported that Biqi, the company’s branded generic anti-diarrhea drug, has passed EU-GMP inspection. The certificate was issued following an audit that covered product formulation, manufacturing process, facilities and quality management systems. In 2010, Simcere's manufacturing facility for diosmectite, the API in Biqi, successfully passed EU-GMP inspection. Simcere makes innovative cancer treatments and branded generics, all of which are distributed in China. Simcere should now be able to market Biqi in Europe, though it did not announce any plans to do so. More details....

Stock Symbol: (NYSE: SCR)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...